Clinical trial of iGS4000 for reducing side effects of anticancer drugs in breast cancer patients

Clinical trial to evaluate the effectiveness of iGS4000 in reducing side effects in breast cancer patients (stages I-III) undergoing hormone therapy or chemotherapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031260028

Enrollment

Registered

2026-04-07

Start date

2026-04-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Breast cancer

Interventions

Intake iGS4000(containing grape seed extract 1350mg/day) every day for 12 weeks

D056604

grape seed extract

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Breast cancer patients (stage I-II) undergoing hormone therapy or chemotherapy

Exclusion criteria

Exclusion criteria: Participants in other clinical trials

Design outcomes

Primary

Measure	Time frame
1) Immunological tests: CEA, CA15-3, BCA225, NCC-ST-439 in serum 2) Doctor's findings on efficacy 3) subjective questionnaire	—

Secondary

Measure	Time frame
1) Immunological tests: HER2, INF-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17, TNF-alpha in serum	—

Contacts

Public ContactTakashi Koikeda

Shiba Palace Clinic

shiba_palace@s-palace-clinic.com+81-3-5408-1590

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026